Tumor-informed cancer genomics testing for MRD detection and therapy selection
Personalis runs a clinical genomics lab in Fremont, pairing a lab stack (LIMS, Qubit, TapeStation) with a Python/Java engineering layer on AWS using Flask, FastAPI and PostgreSQL. Hiring is accelerating and weighted toward healthcare, ops, research and quality rather than software, and job posts repeatedly cite rising sample volume, assay validation deadlines and multi-framework audits. That mix points to a lab scaling clinical throughput under regulatory pressure.
Personalis, Inc. is a public biotechnology company founded in 2011 and headquartered in Fremont, California. It develops sequencing-based cancer tests that compare tumor and normal tissue to track minimal residual disease and recurrence, guide targeted therapy selection through broad genomic profiling, and support biomarker work for drug developers. Its scientific focus spans NGS, immunogenomics, the tumor microenvironment and HLA typing. The company employs between 201 and 500 people and currently hires in the United States.
Personalis uses LIMS, Python, Java, AWS, PostgreSQL, MySQL, Flask, FastAPI, React, Docker, GitLab and Bitbucket, plus Salesforce Service Cloud, Tableau, Power BI, QAD and Jira.
Yes. Hiring is accelerating in the United States, concentrated in healthcare, operations, research and quality roles, with smaller openings in engineering, finance, product and support.
Job posts point to assay development and validation studies, NGS library preparation, LIMS and cloud platform work, a global internal audit program and new precision medicine products.
Other companies in the same industry, closest in size
Personalis, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.